Patents Assigned to Eli Lilly
  • Phenyl acetamides as sPLA2 inhibitors
    Patent number: 6353128
    Abstract: A class of novel phenyl acetamides is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Richard Waltz Harper, David Kent Herron
  • Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
    Patent number: 6353008
    Abstract: The present invention provides the compounds of the following formula (I): and a method for inhibiting the reuptake of seretonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of formula (I).
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Larry Wayne Hertel, Yao-Chang Xu
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6353027
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Method for reducing levels of homocysteine and C-reactive protein
    Patent number: 6353003
    Abstract: The current invention relates to a method for decreasing levels of homocysteine and/or C-reactive protein in humans comprising administering to a mammal in need thereof an effective amount of a compound of formula I: or a pharmaceutical salt or solvate thereof.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventor: Pamela Wang Anderson
  • Streptococcus pneumoniae gene sequence FtsZ
    Patent number: 6350866
    Abstract: The invention provides isolated nucleic acid compounds encoding FtsZ of Streptococcus pneumoniae. Also provided are vectors and transformed host cells for expressing the encoded protein, and a method for identifying compounds that bind and/or inhibit said protein.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: February 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Paul Luther Skatrud, Robert Brown Peery, Q May Wang, Paul Robert Rosteck, Jr., Pamela Kay Rockey
  • Acrylic and propionic acid compounds, intermediates, processes, compositions, and method
    Patent number: 6350884
    Abstract: This invention is directed to a class of acrylic and propionic acid compounds and their use in the treatment of post-menopausal symptoms and restenosis. In other embodiments, the invention is directed to intermediates and to processes for the preparation of the acrylic and propionic acid compounds.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: February 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Charles David Jones, Alan David Palkowitz, Kenneth Jeff Thrasher
  • Antithrombotic agents
    Patent number: 6350774
    Abstract: This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: February 26, 2002
    Assignee: Eli Lilly And Company
    Inventors: Nicholas J Bach, Jolie A. Bastian, Nickolay Y Chirgadze, Michael L Denney, Robert J. Foglesong, Richard W Harper, Mary G Johnson, Ho-Shen Lin, Michael P Lynch, Jefferson R McCowan, Alan D Palkowitz, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Minsheng Zhang
  • Methods for treating sepsis
    Patent number: 6344197
    Abstract: The present invention provides a method of treatment for patients with sepsis. The claimed treatment is a combination therapy with protein C and BPI protein. Combining protein C, with its anti-coagulant/anti-inflammatory properties, and BPI, with its bactericidal and endotoxin neutralizing activities, provides an effective, synergistic therapy for sepsis that will reduce or ameliorate the adverse events and improve the clinical outcome of septic patients.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: February 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Arylpiperazines as serotonin reuptake inhibitors and 5-HT1D&agr; antagonists
    Patent number: 6342498
    Abstract: Anylpiperazines of formula (1) useful as serotonin reuptake inhibitors and 5-HT1D&agr; receptor antagonists are disclosed herein: wherein R1 and R2 are each independently hydrogen, halo, —(C1-C6)alkyl or —(C1-C6)alkoxy; R3 is hydrogen or —(C1-C6)alkyl; Y is —CO— or —CH2—; Z is —NH—, —N(COR)— or —CH2— where R is —(C1-C6)alkyl or —(C3-C8)cycloalkyl; represents a double or single bond; n and m are an each independently integer from 1 to 3, both inclusive; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: January 29, 2002
    Assignee: Eli Lilly and Company
    Inventors: Clint Duane Walker, David Taiwai Wong, Yao-Chang Xu
  • Formulations for controlling human lice
    Patent number: 6342482
    Abstract: Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: January 29, 2002
    Assignee: Eli Lilly and Company
    Inventor: Daniel Earl Snyder
  • SPLA2 inhibitor compounds for treatment of disease
    Patent number: 6340699
    Abstract: The present invention is directed to compounds for treating inflammatory bowel disease. More specifically, the present invention is directed to 1H-indole-3-glyoxyamide compounds a sPLA2 inhibitors for treating inflammatory bowel disease.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: January 22, 2002
    Assignee: Eli Lilly and Company
    Inventor: William Louis Macias
  • 2-acylaminopropanamines as tachykinin receptor antagonists
    Patent number: 6339094
    Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: January 15, 2002
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
  • Method for administering acylated insulin
    Patent number: 6335316
    Abstract: The invention relates to a method of administering a fatty acid-acylated insulin or insulin analog by inhalation, a method for treating diabetes by administering a fatty acid-acylated insulin or insulin analog by inhalation, and a method for treating hyperglycemia by administering a fatty acid-acylated insulin or insulin analog by inhalation.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: January 1, 2002
    Assignee: Eli Lilly and Company
    Inventors: Benjamin Lee Hughes, Ronald Keith Wolff
  • N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6333351
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: December 25, 2001
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: Jing Wu, Eugene D. Thorsett, Jeffrey S. Nissen, Thomas E. Mabry, Lee H. Latimer, Varghese John, Lawrence Y. Fang, James E. Audia
  • Pharmaceutical compounds
    Patent number: 6329366
    Abstract: A pharmaceutical compound of the formula in which R1 and R2 are each hydrogen, halo, cyano or methyl, the dotted line represents an optional double bond, where R4 and R5 are each hydrogen, C1-6 alkyl, cyclopropyl or cyclopropyl-C1-6 alkyl, n is 0 or 1, and R3 is —SR6, —SOR6, —SO2R6, —COR6, —CH2OH or —CONHR7, where R6 is C1-6 alkyl and R7 is hydrogen or C1-6 alkyl; provided that when one of R1 and R2 is hydrogen and the other is fluoro, R4 and R5 are each hydrogen or C1-6 alkyl, and n is 0, then R3 is not —COR6 or —CONHR7; and salts thereof.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company Limited
    Inventors: John Fairhurst, Peter Thaddeus Gallagher, Martin Victor Miles
  • Crystalline form of dihydro-2,3-benzodiazepine derivative
    Patent number: 6329364
    Abstract: A physical form of (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 12.78, 9.48, 8.99, 8.64, 8.23, 6.39, 6.27. 5.73, 4.01 and 3.96 Å. The compound is useful as an AMPA antagonist.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventor: Edward G. Groleau
  • Treatment of congestive heart failure with growth hormone secretagogues
    Patent number: 6329342
    Abstract: The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Kauffman, Alan D. Palkowitz
  • Cephalosporin antibiotics
    Patent number: 6329363
    Abstract: The invention provides new fluorinated cephalosporin antibiotics and methods of preventing or treating infection, particularly mastitis in ruminants, using these antibiotics, and veterinary and pharmaceutical formulations comprising these antibiotics.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventor: Karl Robert Dahnke
  • Recombinant DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium
    Patent number: 6322998
    Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
  • Beta-lipotropin methods
    Patent number: 6323178
    Abstract: The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: John Edward Hale, Mark Louis Heiman, Brigitte Elisabeth Schoner, William Francis Heath, Jr.